Heart Failure Society Of America 17th Annual Scientific Meeting To Focus On New Developments In Heart Failure Cause, Care And Treatment
ORLANDO, Sept. 22, 2013 /PRNewswire/ -- The Heart Failure Society of America's (HFSA) 17 th Annual Scientific Meeting convenes Sunday, September 22, 2013 at the Peabody Orlando Hotel. This four-day meeting--a forum for heart failure specialists to present research findings and advances in treatment--will address emerging trends in research and new developments in the approach to treating patients with all stages of heart failure.
The 2013 HFSA Lifetime Achievement Award will be presented to Dr. Arthur Feldman, M.D. Ph.D., Executive Dean of Temple University School of Medicine. Dr. Feldman has received numerous awards and has been a member of several professional societies. Dr. Feldman is a renowned cardiovascular researcher who has led many clinical trials, and his work on the molecular biology of heart failure has been published in over 200 peer-reviewed articles. In addition, Dr. Feldman is a past president of the Heart Failure Society of America, and during his tenure he developed and implemented Heart Failure Awareness week.
"We are delighted to honor Dr. Art Feldman with this year's Lifetime Achievement Award," said Dr. Thomas Force, HFSA President. "Art is a distinguished clinician and researcher, and he has contributed a great deal to the field of heart failure."
The scientific program will kick off with an opening plenary session: "The Impact of Healthcare Reform" on Monday, September 23 at 8:00 a.m.Following the opening plenary will be simultaneous sessions with presentations by national and international heart failure experts, scientists, and allied health care professionals. Many will focus on the progressive treatments for heart failure and the increased risks patients face, along with recent developments related to devices and healthcare reform. "This year's annual meeting will feature many exciting new advances in the field of heart failure, specifically in the areas of readmissions and heart failure in patients with comorbidities," said Dr. Force. "The conference will once again feature the latest developments in clinical trials and new research from the leading practitioners and scientists interested in heart failure. Thought leaders in the field will discuss causes and treatment of heart failure and the important socio-economic issues surrounding this condition, along with the impact of healthcare reform."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts